

## 1st Early Stage Health Researcher Forum

The Research & Education Foundation (REF) hosts an event for early stage health researchers (ESRs) on Thursday, 24<sup>th</sup> November at Sligo University Hospital. The event will give early researchers an opportunity to present on work-in-progress health-related research projects followed by a feedback session from a panel of experts.

### When?

Thursday, November 24th, 2022, 2 pm – 5 pm

### Where?

Lecture Theatre, Level 6, Sligo University Hospital

### Who can attend?

Early stage health researchers, nurses, medical and allied health care professionals, anyone interested and engaged in health research

### Benefits to attendees:

- Free pre-conference event focusing exclusively on ESRs
- A chance to present your work-in-progress and obtain expert feedback
- A chance to present a work-in-progress poster during the Poster Exhibition
- A chance to win “Best Presenter” award, to be announced at the 23<sup>rd</sup> Annual Multidisciplinary Research Conference

### Who can present?

To be eligible to present, you will need to:

- Be an early stage health researcher<sup>\*)</sup>
- Be able to attend the full event in-person
- Submit an abstract by Sunday October 2<sup>nd</sup> 2022

<sup>\*)</sup> ‘Early stage health researchers’ (ESRs) are defined as individuals working in the area of health/academia who are less than 5 years health research active (full-time equivalent research experience). Our definition of ECRs includes postgraduate students, doctoral students, post-doctoral researchers, medical doctors, nurses and allied healthcare professionals and equivalent.

### Abstract Submission

**To be selected as speaker**, you will need to submit an abstract about a work-in-progress, i.e., current research that is not yet completed. This could include, for example, research you are currently conducting, or research that is completed but requires further interpretation prior to wider dissemination.

## Selection Process

The Research Advisory Committee and external reviewers will review and score submissions. Abstracts from early stage researchers will be selected for presentation at the event. Abstracts are selected on the basis of their medical and scientific significance, timeliness, quality of data and methodology, potential impact and adherence to specific format requirements described below.

## Accepted Abstracts

Abstracts will be accepted for presentation and poster OR poster only.

If your abstract is selected for presentation at the early stage researcher forum, you will be asked to prepare a 5-minute presentation about your work-in-progress. After each block of presentations, there will be a 15-minute Q&A session to obtain feedback, questions, and suggestions from an expert panel and other attendees. ESRs with accepted abstracts are also invited to prepare a poster about their work-in-progress to be displayed at the Poster Exhibition from November 17<sup>th</sup> to December 1<sup>st</sup> in the SUH and ATU.

Submit abstract for the 1st Early Stage Health Researcher Forum by emailing the completed abstract submission form as pdf document to [office@ref-sligo.ie](mailto:office@ref-sligo.ie).

ABSTRACT SUBMISSION CLOSES: Sunday, October 2<sup>nd</sup> 2022.

ABSTRACT SUBMISSION IS OPEN NOW.

If your abstract is not selected for poster or presentation you are welcome to come and attend the event and learn about what research is happening locally.

## Abstract Guidance

### ABSTRACT TITLE

The abstract title should be concise, clearly convey the subject of the abstract and not exceed a maximum of 20 words.

### AUTHORS

**Requirements for Authorship:** Authors listed in the abstract should conform to the International Committee of Medical Journal Editors (ICMJE) recommendations for authorship:

- 1 Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- 2 Drafting the work or revising it critically for important intellectual content; AND
- 3 Final approval of the version to be submitted; AND
- 4 Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

The author order indicates the magnitude of contribution, with the first author adding the most value and the last author representing the most senior, predominantly supervisory role.

Those whose contributions do not qualify for or justify authorship should be acknowledged individually or together as a group under 'Contributorship' (e.g. "Clinical Investigators" or "Participating Investigators"), and their contributions should be specified (e.g., "served as scientific advisors", "critically reviewed the study proposal", "collected data", "provided and cared for study patients", "participated in writing or technical editing of the manuscript").

See: [Defining the Role of Authors and Contributors](#); International Committee of Medical Journal Editors (ICMJE);

## **ABSTRACT TEXT**

The abstract length should not exceed 500 words, excluding the title and authors. Tables, figures and footnotes are not allowed and any acknowledgements should be given within the paragraph. Please note that word counts will be checked and abstracts that do not adhere to these guidelines will be rejected.

Please structure your abstract using sub-headings as shown below. Since abstracts will refer to work-in-progress, not all sub-headings may apply (for example, you may not have any results to share yet). Please highlight some key challenges in your abstract regarding your current work that you would like feedback on. Abstract structure as follows:

- **Introduction/ Background**
- **Aims & Objectives**
- **Methodology/ Materials**
- **Preliminary results** (if applicable)
- **Challenges**
- **Impact**
- **Conclusions.**

## **REFERENCES**

Incorporate inline citation, using superscript numbers (e.g.,<sup>1, 2</sup>) within the text of the abstract (Vancouver Reference style). Not included in the word count of the abstract.

## **CONTRIBUTORSHIP**

We encourage authors to fully acknowledge the contribution of e.g. who had the idea for the study, who performed the literature search, who wrote the article, who is the guarantor (the contributor who accepts full responsibility for the finished article, had access to any data, and controlled the decision to publish) and of patients and the public where appropriate.

## **CONFLICT OF INTEREST**

None Disclosed/Payment received from .....

## **FUNDING**

No Funding/Research relating to this abstract was funded by .....

**For any questions on abstract submission guidelines, please email Susanna, [office@ref-sligo.ie](mailto:office@ref-sligo.ie).**

## Confirmation of Receipt

Submitting authors will be sent an acknowledgement via e-mail to confirm that their abstract has been received. If you do not receive the acknowledgement within three working days of your submission, please contact the [office@ref-sligo.ie](mailto:office@ref-sligo.ie).

**Abstract Submission Form:** click [here](#) or request from [office@ref-sligo.ie](mailto:office@ref-sligo.ie).

**The REF is not responsible for the content within each presentation and it is not representative of the opinions of REF.**